Gilead Sciences, Inc. $GILD Shares Acquired by Tectonic Advisors LLC

Tectonic Advisors LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 93,682 shares of the biopharmaceutical company’s stock after buying an additional 5,356 shares during the quarter. Tectonic Advisors LLC’s holdings in Gilead Sciences were worth $10,399,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GILD. Brighton Jones LLC boosted its stake in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC purchased a new stake in Gilead Sciences during the 4th quarter worth $215,000. Focus Partners Advisor Solutions LLC lifted its holdings in Gilead Sciences by 62.7% in the 1st quarter. Focus Partners Advisor Solutions LLC now owns 8,064 shares of the biopharmaceutical company’s stock worth $904,000 after buying an additional 3,107 shares in the last quarter. Federation des caisses Desjardins du Quebec boosted its position in Gilead Sciences by 7.4% in the 1st quarter. Federation des caisses Desjardins du Quebec now owns 95,135 shares of the biopharmaceutical company’s stock valued at $10,665,000 after buying an additional 6,563 shares during the last quarter. Finally, AQR Capital Management LLC boosted its position in Gilead Sciences by 2.8% in the 1st quarter. AQR Capital Management LLC now owns 1,864,670 shares of the biopharmaceutical company’s stock valued at $207,370,000 after buying an additional 51,116 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $124.83, for a total value of $1,248,300.00. Following the completion of the transaction, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at approximately $70,740,911.34. The trade was a 1.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. This represents a 35.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 136,257 shares of company stock valued at $16,855,192 in the last ninety days. 0.27% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on GILD. Needham & Company LLC lifted their target price on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Royal Bank Of Canada raised their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company a “sector perform” rating in a research note on Friday, October 31st. Citigroup upped their target price on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday, October 8th. Scotiabank assumed coverage on Gilead Sciences in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 target price for the company. Finally, Wall Street Zen downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 20th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $131.68.

Gilead Sciences Trading Down 0.4%

Shares of NASDAQ GILD opened at $122.74 on Friday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The stock’s 50 day moving average price is $123.04 and its two-hundred day moving average price is $116.97. Gilead Sciences, Inc. has a 52-week low of $88.57 and a 52-week high of $128.70. The stock has a market capitalization of $152.28 billion, a P/E ratio of 19.03, a PEG ratio of 0.68 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were paid a dividend of $0.79 per share. The ex-dividend date was Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.6%. Gilead Sciences’s payout ratio is presently 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.